Get started
Author

Scott Pain

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
2022 · Emmanuel Mignot, David Mayleben, et al. · The Lancet Neurology · 257
Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT)
2016 · Julie Bernhardt, Leonid Churilov, et al. · Neurology · 220
PDF
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
2020 · Yves Dauvilliers, Gary Zammit, et al. · Annals of Neurology · 147
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder
2020 · Gary Zammit, Yves Dauvilliers, et al. · Neurology · 104
Phase 1/1 B trial of the heat shock protein 90 inhibitor NVP ‐ AUY 922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
2015 · Ruth Seggewiss‐Bernhardt, Ralf C. Bargou, et al. · Cancer · 73
PDF
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
2022 · Ingo Fietze, Claudio L. A. Bassetti, et al. · Drugs & Aging · 57
PDF
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
2015 · A Spreafico, J-P Delord, et al. · British Journal of Cancer · 37
PDF
Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial
2023 · Susan L. McElroy, Preciosa M. Coloma, et al. · International Journal of Eating Disorders · 21
Efficacy and safety of daridorexant for the treatment of insomnia disorder in women of menopausal transition age: Insights from a randomized controlled trial
2025 · Zoe Schaedel, Talitha R. Bakker, et al. · Maturitas · 6
Effects of daridorexant on sleep and daytime functioning in older adults with insomnia
2022 · Ingo Fietze, Claudio Bassetti, et al. · American Journal of Geriatric Psychiatry · 6
348 Absence of Withdrawal Symptoms and Rebound Insomnia Upon Discontinuation of Daridorexant in Patients with Insomnia
2021 · Damien Leger, Ingo Fietze, et al. · SLEEP · 5
PDF
0521 Daridorexant (ACT-541468), A Dual Orexin Receptor Antagonist for the Treatment of Insomnia Disorder: Double Blind, Randomized, Phase 3 Studies for Efficacy and Safety in Adult and Elderly Patients
2020 · G Zammit, D Seboek Kinter, et al. · SLEEP · 4
Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
2013 · Leticia De Mattos-Arruda, Lillian L. Siu, et al. · Journal of Clinical Oncology · 4
347 Daridorexant is Safe and Improves Both Sleep and Daytime Functioning in Elderly Patients with Insomnia
2021 · Ingo Fietze, Claudio Bassetti, et al. · SLEEP · 3
0375 A Novel Dual Orexin Receptor Antagonist (ACT-541468) to Treat Insomnia: A Randomized, Double-Blind, Placebo-Controlled, Active-Reference Phase 2 Study
2019 · Yves Dauvilliers, Gary Zammit, et al. · SLEEP · 2
Effect of daridorexant on wakefulness throughout the night: Post-hoc analysis of a randomised, double-blind, active reference (zolpidem) study in patients with insomnia disorder
2025 · B. Steiniger-Brach, O. Briasoulis, et al. · European Psychiatry · 1
PDF
344 Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep Stages
2021 · Gary Zammit, David Mayleben, et al. · SLEEP · 1
0407 ACT-541468, A Dual Orexin Receptor Antagonist, For The Treatment Of Insomnia Disorder: A Randomized, Double-Blind, Placebo-Controlled, 5-Period, 5-Treatment Crossover Dose-Response Phase 2 Study In The Elderly
2019 · Gary Zammit, Yves Dauvilliers, et al. · SLEEP · 1
PDF
P-0303 Safety and Tolerability data from A Phase II Study of Auy922 Compared with Chemotherapy in Patients with Advanced Gastric Cancer
2012 · Kun-Huei Yeh, Jen-Shi Chen, et al. · Annals of Oncology · 1
PDF
313. Effect of daridorexant on wakefulness throughout the night: post-hoc analysis of a randomised, double-blind, active reference (zolpidem) study in patients with insomnia disorder
2026 · B Steiniger-Brach, O Briasoulis, et al. · The International Journal of Neuropsychopharmacology
PDF
O12 Efficacy and safety of daridorexant in women with insomnia disorder during menopausal transition: a subgroup analysis
2026 · Zoe Schaedel, Orestis Briasoulis, et al.
Efficacy and safety of daridorexant in women with insomnia disorder during menopausal transition: a subgroup analysis
2026 · O. Briasoulis, Z. Schaedel, et al. · Sleep Medicine
Effect of daridorexant on wakefulness throughout the night: Post-hoc analysis of a randomised, double-blind, active reference (zolpidem) study in patients with insomnia disorder
2026 · B. Steiniger-Brach, O. Briasoulis, et al. · Sleep Medicine
3052 Efficacy and safety of daridorexant in patients >65 years with insomnia
2025 · L Petrikaitis, I Fietze, et al. · Age and Ageing
Time to therapeutic effect with daridorexant: Weekly analysis of patient-reported outcomes from a Phase 3 randomized, placebo-controlled study in patients with insomnia disorder
2025 · T. R. Bakker, O. Briasoulis, et al. · European Psychiatry
PDF
Works count: 32
Citation count: 950
H-index: 8
I10-index: 8
Year
Topic
Type